Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel
NCT ID: NCT01839968
Last Updated: 2014-08-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
32 participants
OBSERVATIONAL
2011-09-30
2014-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
NCT00910299
Prasugrel Versus Clopidogrel to TREAT High Platelet Reactivity
NCT01493999
CRUSHed vs. Uncrushed Prasugrel in STEMI Patients Undergoing PCI
NCT03296540
Platelet Inhibition in Patients With Systolic Heart Failure
NCT01765400
The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel
NCT01365221
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study patients
Acute coronary syndrome patients with a recent loading dose of prasugrel (6-24h)
Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Prasugrel loading dose 6-24h before inclusion
Exclusion Criteria
* GPIIbIIIa use within 10 days before inclusion
* Known congenital thrombopathy and/or congenital coagulation defect
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Geneva
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fanny Bonhomme
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Geneva
Geneva, Canton of Geneva, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-117
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.